For the quarter ending 2025-09-30, VXRT had -$3,231K decrease in cash & cash equivalents over the period. $2,478K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,141 | -30,577 |
| Depreciation and amortization | 2,080 | 4,444 |
| Loss on disposal of assets | -5 | - |
| Net (accretion) amortization of (discounts) premiums on investments | 42 | 165 |
| Stock-based compensation | 2,018 | 4,580 |
| Non-cash interest expense related to sale of future royalties | 607 | 1,670 |
| Non-cash revenue related to sale of future royalties | 0 | 4,521 |
| Accounts receivable | 38,435 | -1,480 |
| Unbilled receivable from government contracts | 6,448 | 30,573 |
| Prepaid expenses and other assets | -417 | -1,534 |
| Prepaid clinical services, long-term | 0 | - |
| Accounts payable | 42,570 | 3,648 |
| Deferred revenue-Government Contract | -549 | -23 |
| Other accrued liabilities | 8,513 | 22,959 |
| Net cash used in operating activities | 2,595 | -25,544 |
| Purchases of property and equipment | 117 | 27 |
| Proceeds from sale of property and equipment | 5 | - |
| Purchases of investments | 9,410 | 9,808 |
| Proceeds from maturities of investments | 3,700 | 30,300 |
| Net cash provided by (used in) investing activities | -5,822 | 20,465 |
| Net proceeds from issuance of common stock-June2024Offering | 0 | 0 |
| Net proceeds from issuance of common stock-Atthemarket Facility | 0 | 53 |
| Net proceeds from issuance of common stock-RACapital Healthcare Fund2024 | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 | 3 |
| Shares acquired to settle employee tax withholding liabilities | 4 | 174 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 0 | 0 |
| Proceeds from issuance of treasury stock under the employee stock purchase plan | 0 | 79 |
| Net cash (used in) provided by financing activities | -4 | -39 |
| Net decrease in cash and cash equivalents | -3,231 | -5,118 |
| Cash and cash equivalents at beginning of period | 25,229 | - |
| Cash and cash equivalents at end of period | 16,880 | - |
Vaxart, Inc. (VXRT)
Vaxart, Inc. (VXRT)